The Impact of Company-Level ART Provision to a Mining Workforce in South Africa: A Cost–Benefit Analysis

1. Rosen S, Simon J, MacLeod W, Fox M, Thea DM. AIDS is your business. Harv Bus Rev. 2003;81:5–11.

2. Rosen S, Vincent JR, MacLeod W, Fox M, Thea DM, Simon JL. The cost of HIV/AIDS to businesses in southern Africa. AIDS. 2004;18:317–324. 15075551

3. Rosen S, Feeley F, Connelly P, Simon J. The private sector and HIV/AIDS in Africa: taking stock of 6 years of applied research. AIDS. 2007;21 Suppl 3:S41–S51. 17666961

4. Rajak D. ‘HIV/AIDS is our business’: the moral economy of treatment in a transnational mining company. J R Anthropol Inst. 2010;16:551–571.

5. Brink B, Pienaar J. Business and HIV/AIDS: the case of Anglo American. AIDS. 2007;21 Suppl 3:S79–S84. 17666965

6. Greener R. Impact of HIV/AIDS and options for intervention: results of a five company pilot study. Working Paper No. 10. Gaborone: Botswana Institute of Development Policy Analysis; 1997.

7. Feeley F, Bukuluki P, Collier A, Fox M. The impact of HIV/AIDS on productivity and labor costs in two Ugandan corporations. Boston: Center for International Health and Development, Boston University; 2004.

8. AIDS Control and Prevention Project. Private sector AIDS policy: African workplace profiles. Washington (District of Columbia): Family Health International; 1995.

9. Fox MP, Rosen S, MacLeod WB, Wasunna M, Bii M, Foglia G, et al. The impact of HIV/AIDS on labour productivity in Kenya. Trop Med Int Health. 2004;9:318–324. 14996359

10. Joint United Nations Programme on HIV/AIDS. Global report: UNAIDS report on the global AIDS epidemic 2013. Geneva: Joint United Nations Programme on HIV/AIDS; 2013.

11. Shisana O, Rehle T, Simbayi LC, Zuma K, Jooste S, Pillay-van-Wyk V, et al. South African national HIV prevalence, incidence, behaviour and communication survey, 2008: a turning tide among teenagers? Cape Town: HSRC Press; 2009.

12. Shisana O, Rehle T, Simbayi LC, Zuma K, Jooste S, Zungu N, et al. South African national HIV prevalence, incidence and behaviour survey, 2012. Cape Town: HSRC Press; 2014.

13. Evian C, Fox M, MacLeod B, Slotow S, Rosen S. Prevalence of HIV in workforces in southern Africa, 2000–2001. S Afr Med J. 2004;94:125–130. 15034992

14. Harling G, Wood R. The evolving cost of HIV in South Africa: changes in health care cost with duration on antiretroviral therapy for public sector patients. J Acquir Immune Defic Syndr. 2007;45:348–354.

15. Rosen S, Ketlhapile M, Sanne I, Bachman DeSilva M. Cost to patients of obtaining treatment for HIV/AIDS in South Africa. S Afr Med J. 2007;97:524–529. 17805455

16. Rosen S, Long L, Sanne I. The outcomes and outpatient costs of different models of antiretroviral treatment delivery in South Africa. Trop Med Int Health. 2008;13:1005–1015. doi: 10.1111/j.1365-3156.2008.02114.x 18631314

17. Rosen S, Long L, Fox M, Sanne I. Cost and cost-effectiveness of switching from stavudine to tenofovir in first-line antiretroviral regimens in South Africa. J Acquir Immune Defic Syndr. 2008;48:334–344.

18. Stearns BK, Evans DK, Lutung P, Wagner G, Ryan G, Aledort JE. Primary estimates of the costs of ART care at 5 AHF clinics in sub-Saharan Africa. Abstract MOPE0706. XVIIth International AIDS Conference; 3–8 Aug 2008; Mexico City, Mexico.

19. Leisegang R, Cleary S, Hislop M, Davidse A, Regensberg L, Little F, et al. Early and late direct costs in a Southern African antiretroviral treatment programme: a retrospective cohort analysis. PLoS Med. 2009;6:e1000189. doi: 10.1371/journal.pmed.1000189 19956658

20. Martinson N, Mohapi L, Bakos D, Gray LE, McIntyre JA, Holmes CB. Costs of providing care for HIV-infected adults in an urban HIV clinic in Soweto, South Africa. J Acquir Immune Defic Syndr. 2009;50:327–330.

21. Kevany S, Meintjes G, Rebe K, Maartens G, Cleary S. Clinical and financial burdens of secondary level care in a public sector antiretroviral roll-out setting (G F Jooste Hospital). S Afr Med J. 2009;99:320–325. 19588792

22. Long L, Fox M, Sanne I, Rosen S. The high cost of second-line antiretroviral therapy for HIV/AIDS in South Africa. AIDS. 2010;24:915–919. doi: 10.1097/QAD.0b013e3283360976 20042849

23. Long L, Brennan A, Fox MP, Ndibongo B, Jaffray I, Sanne I, et al. Treatment outcomes and cost-effectiveness of shifting management of stable ART to nurses in South Africa: an observational cohort. PLoS Med. 2011;8:e1001055. doi: 10.1371/journal.pmed.1001055 21811402

24. Cleary S, Blecher M, Boulle A, Dorrington R, Darkoh E, Bogopane-Zulu H. The costs of the National Strategic Plan on HIV and AIDS & STIs 2007–2011. Cape Town: University of Cape Town, National Treasury, Broadreach Health Care, and South African Parliament; 2007. doi: 10.1080/17441692.2013.790461 23651436

25. Meyer-Rath G, Brennan A, Long L, Ndibongo B, Technau K, Moultrie H, et al. Cost and outcomes of paediatric antiretroviral treatment in South Africa. AIDS. 2012;27:243–250.

26. Meyer-Rath G, Miners A, Santos A, Variava E, Venter F. Cost and resource use of patients on antiretroviral therapy in the urban and semi-urban public sectors of South Africa. J Acquir Immune Defic Syndr. 2012;61:e25–e32. doi: 10.1097/QAI.0b013e31826cc575 22895437

27. Meyer-Rath G, Brennan A, Fox MP, Modisenyane T, Tshabangu N, Mohapi L, et al. Rates and cost of hospitalisation before and after initiation of antiretroviral therapy in the urban and rural public sector of South Africa. J Acquir Immune Defic Syndr. 2013;62:322–328. 23187948

28. Leisegang R, Maartens G, Hislop M, Sargent J, Darkoh E, Cleary S. A novel Markov model projecting costs and outcomes of providing antiretroviral therapy to public patients in private practices versus public clinics in South Africa. PLoS ONE. 2013;8:e53570. doi: 10.1371/journal.pone.0053570 23405073

29. Cleary S, McIntyre D, Boulle A. The cost-effectiveness of antiretroviral treatment in Khayelitsha, South Africa—a primary data analysis. Cost Eff Resour Alloc. 2006;4:20. 17147833

30. Badri M, Maartens G, Mandalia S, Bekker L-G, Penrod JR, Platt RW, et al. Cost-effectiveness of highly active antiretroviral therapy in South Africa. PLoS Med. 2006;3:e4. 16318413

31. Bachmann MO. Effectiveness and cost effectiveness of early and late prevention of HIV/AIDS progression with antiretrovirals or antibiotics in Southern African adults. AIDS Care. 2006;18:109–120. 16338768

32. Holmes CB, Zheng H, Martinson NA, Freedberg KA, Walensky RP. Optimizing treatment for HIV-infected South African women exposed to single-dose nevirapine: balancing efficacy and cost. Clin Infect Dis. 2006;42:1772–1780. 16705586

33. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373:48–57. doi: 10.1016/S0140-6736(08)61697-9 19038438

34. Cleary S, Mooney G, McIntyre D. Equity and efficiency in HIV-treatment in South Africa: the contribution of mathematical programming to priority setting. Health Econ. 2009;19:1166–1180.

35. Cleary S, McIntyre D. Financing equitable access to antiretroviral treatment in South Africa. BMC Health Serv Res. 2010;10 Suppl 1:S2. doi: 10.1186/1472-6963-10-S1-S2 20594368

36. Walensky RP, Wolf LL, Wood R, Fofana MO, Freedberg KA, Martinson NA, et al. When to start antiretroviral therapy in resource-limited settings. Ann Int Med. 2009;151:157–166. 19620143

37. Walensky RP, Wood R, Ciaranello AL, Paltiel AD, Lorenzana SB, Anglaret X, et al. Scaling up the 2010 World Health Organization HIV treatment guidelines in resource-limited settings: a model-based analysis. PLoS Med. 2010;7:e1000382. doi: 10.1371/journal.pmed.1000382 21209794

38. Wagner B, Blower S. Costs of eliminating HIV in South Africa have been underestimated. Lancet. 2010;376:953. doi: 10.1016/S0140-6736(10)61442-0 20851250

39. Hontelez JAC, de Vlas SJ, Tanser F, Bakker R, Bärnighausen T, Newell ML, et al. The impact of the new WHO antiretroviral treatment guidelines on HIV epidemic dynamics and cost in South Africa. PLoS ONE. 2011;6:e21919. doi: 10.1371/journal.pone.0021919 21799755

40. Bendavid E, Grant P, Talbot A, Owens DK, Zolopa A. Cost-effectiveness of antiretroviral regimens in the World Health Organization’s treatment guidelines: a South African analysis. AIDS. 2011;25:211–220. doi: 10.1097/QAD.0b013e328340fdf8 21124202

41. Ciaranello AL, Lockman S, Freedberg KA, Hughes M, Chu J, Currier J, et al. First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial. AIDS. 2011;25:479–492. doi: 10.1097/QAD.0b013e3283428cbe 21293199

42. Hallett TB, Baeten JM, Heffron R, Barnabas R, de Bruyn G, Cremin Í, et al. Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study. PLoS Med. 2011;8:e1001123. doi: 10.1371/journal.pmed.1001123 22110407

43. Eaton JW, Menzies NA, Stover J, Cambiano V, Chindelevitch L, Cori A, et al. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. Lancet Glob Health. 2013;2:23–34. doi: 10.1016/S2214-109X(13)70172-4 25083415

44. Granich R, Kahn JG, Bennett R, Holmes CB, Garg N, Serenata C, et al. Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011–2050. PLoS ONE. 2012;7:e30216. doi: 10.1371/journal.pone.0030216 22348000

45. Alistar SS, Grant PM, Bendavid E. Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa. BMC Med. 2014;12:46. doi: 10.1186/1741-7015-12-46 24629217

46. Larson BA, Fox MP, Rosen S, Bii M, Sigei C, Shaffer D, et al. Early effects of antiretroviral therapy on work performance: preliminary results from a cohort study of Kenyan agricultural workers. AIDS. 2008;22:421–425. doi: 10.1097/QAD.0b013e3282f3cc0c 18195569

47. Larson BA, Fox MP, Rosen S, Bii M, Sigei C, Shaffer D, et al. Do the socioeconomic impacts of antiretroviral therapy vary by gender? A longitudinal study of Kenyan agricultural worker employment outcomes. BMC Public Health. 2009;9:240. doi: 10.1186/1471-2458-9-240 19604381

48. Thirumurthy H, Zivin JG, Goldstein M. The economic impact of AIDS treatment: labor supply in western Kenya. J Hum Resour. 2008;43:511–552. 22180664

49. Fox MP, McCoy K, Larson BA, Rosen S, Bii M, Sigei C, et al. Improvements in physical wellbeing over the first two years on antiretroviral therapy in western Kenya. AIDS Care. 2010;22:137–145. doi: 10.1080/09540120903038366 20390492

50. Habariyamana J, Mbakile B, Pop-Eleches C. The impact of HIV/AIDS and ARV treatment on worker absenteeism- implications for African firms. J Hum Resour. 2010;45:809–839.

51. Marseille E, Saba J, Muyingo S, Kahn JG. The costs and benefits of private sector provision of treatment to HIV-infected employees in Kampala, Uganda. AIDS. 2006;20:907–914. 16549976

52. Ingle SM. Modelling waiting times for HIV antiretroviral therapy in South Africa: patient management, outcomes and treatment rationing strategies in the Free State Province. PhD dissertation. University of Bristol. 2010.

53. Huber A, Pienaar J, Innes C, Felix M, Churchyard GJ, Hoffmann CJ, et al. Impact of universal VCT on population HIV incidence within a cohort of South African coal miners. International AIDS Society Conference; 17–20 July 2011; Rome, Italy.

54. Muirhead D, Kumaranayake L, Pozo-Martin F, Charalambous S, Pemba L, Grant A. Early savings resulting from employer-sponsored ART in a large South African workforce setting. Abstract 652. 2nd South African AIDS Conference; 7–10 June 2005; Durban, South Africa.

55. Charalambous S, Innes C, Muirhead D, Kumaranayake L, Fielding K, Pemba L, et al. Evaluation of a workplace HIV treatment programme in South Africa. AIDS. 2007;21 Suppl 3:S73–S78. 17666964

56. South African Reserve Bank. Repo rate. Available: http://www.resbank.co.za/Research/Rates/Pages/Repo%20Rate.aspx. Accessed 29 July 2015.

57. Briggs AH, Sculpher MJ, Claxton K. Decision modelling for health economic evaluation. 1st ed. Oxford: Oxford University Press; 2006.

58. Meyer-Rath G, Brennan A, Long L, Rosen S, Fox MP. Survival in care and CD4 cell count gain on first‐line ART depend on prior CD4 cell count and time on treatment: evidence from a large South African cohort. Abstract Z-148. 17th Conference on Retroviruses and Opportunistic Infections; 16–19 February 2010; San Francisco, US.

59. Meyer-Rath G, Pillay Y, Blecher M, Brennan A, Long L, Johnson LF, et al: Total cost and potential cost savings of the national antiretroviral treatment (ART) programme in South Africa 2010 to 2017. Abstract WEAE0201. XVIII International AIDS Conference; 18–23 July 2010; Vienna, Austria.

60. Biggs T, Shah M. The impact of the AIDS epidemic on African firms. RPED Discussion Paper #72. Washington (District of Columbia): World Bank, Africa Region; 1997.

61. Morris C, Burdge D, Cheevers E. Economic impact of HIV infection in a cohort of sugar mill workers in South Africa. S Afr J Econ. 2000;68:413–419.

62. Moore D. The AIDS threat and the private sector. AIDS Anal Afr. 1999;9:1–2. 12349149

63. Republic of South Africa Department of Mineral Resources. Amendment of the broad-based socio-economic empowerment charter for the South African mining and minerals industry. Pretoria: Republic of South Africa Department of Mineral Resources; 2010.

64. Brink B. The business case for extractive industry involvement in the fight against AIDS and TB. Abstract MOSS0302. International AIDS Conference; 20–25 July 2014; Melbourne, Australia.